Avanir Pharmaceuticals Announces Publication of AVP-825...

From Migraine News
September 20, 2013 - 10:47am

This randomized study characterized the PK profile of 22 mg sumatriptan delivered through AVP-825 compared with the PK profiles of three sumatriptan products: 20 mg liquid nasal spray, 100 mg oral tablet and 6 mg subcutaneous injection.

Share this article »  

Continue reading this article »